Nektar Therapeutics (NKTR) Amortization of Goodwill (2023)

Nektar Therapeutics' (NKTR) quarterly Amortization of Goodwill came in at $76.5 million in Q1 2023.

Nektar Therapeutics (NKTR) Amortization of Goodwill (2023) Analysis & Trends

Nektar Therapeutics' Amortization of Goodwill history runs 1 years deep, the most recent figure standing at $76.5 million for Q1 2023.

On a quarterly basis, Amortization of Goodwill changed N/A year-over-year to $76.5 million in Q1 2023; TTM through Dec 2023 was $76.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $76.5 million, changed N/A from the prior year.
Amortization of Goodwill steadied at $76.5 million in Q1 2023 per NKTR's latest filing.
Across five years, Amortization of Goodwill topped out at $76.5 million in Q1 2023 and bottomed at $76.5 million in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Nektar Therapeutics	2.04 Bn	1.48 Bn	3.16 Mn

Download Data

Date	Value
Mar 31, 2023	76.50 Mn
Mar 31, 2023	76.50 Mn